NCT00909389
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)
See it on ClinicalTrials.gov ↗4,748 people
50.5%
49.5%
2,400 womenmiddle line = equal numbers2,348 men
- Phase
- —
- Paid for by
- Organon and Co
- Finished
- 2008-11
- Health conditions
- Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 55.53 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnancy or lactation”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnancy or lactation”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Moderate to severe hepatic insufficiency”
Study titles and rules are shown in their original English.